Showing results (131-140 of 279) with videos related to
Sort By:
Pageof 28
European Journal of Cancer (Oxford, England : 1990)|April 11, 2006
Activated ERK1/2 and phosphorylated oestrogen receptor alpha are associated with improved breast cancer survival in women treated with tamoxifenJenny Bergqvist, Goran Elmberger, John Ohd, et al.International Journal of Molecular Medicine|April 8, 2010
The impact of RNA standardization and heterogeneous gene expression on the results of cDNA array of human breast carcinomaReza Khoshnoud, Qimin He, Maria Sylván, et al.International Journal of Cancer|December 29, 2005
Monitoring of disseminated tumor cells in bone marrow in high-risk breast cancer patients treated with high-dose chemotherapyVilde Drageset, Jahn M Nesland, Bjorn Erikstein, et al.The Journal of Pathology. Clinical Research|February 1, 2017
High expression of stromal PDGFRβ is associated with reduced benefit of tamoxifen in breast cancerJanna Paulsson, Lisa Rydén, Carina Strell, et al.The Oncologist|April 17, 2020
Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual DiseaseSahra Ali, Alexandre Moreau, Daniela Melchiorri, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2016
An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast TumorsNicholas P Tobin, Kristian Wennmalm, Linda S Lindström, et al.Leukemia & Lymphoma|January 21, 2003
A novel B-cell line (U-2932) established from a patient with diffuse large B-cell lymphoma following Hodgkin lymphomaRose-Marie Amini, Mattias Berglund, Richard Rosenquist, et al.Cancer Research|August 31, 2011
An iron regulatory gene signature predicts outcome in breast cancerLance D Miller, Lan G Coffman, Jeff W Chou, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 29, 2012
FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancerJonas Bergh, Per-Ebbe Jönsson, Elisabet Kerstin Lidbrink, et al.The American Journal of Pathology|June 6, 2009
Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancerJanna Paulsson, Tobias Sjöblom, Patrick Micke, et al.Pageof 28